newsfilter
← Latest News
Business Wire·

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome, Inc. (the "Company") (NASDAQ:IMNM), a clinical-stage target oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 1, 2026,